SMURF1 and pulmonary arterial hypertension: Furthermore, suppression of miR-21, miR-424(322) and lncRNA SOX2-OT offers potential therapeutic benefits in PAH by upregulating WWP1/SMURF1 or downregulating SUMO1 (110, 111, 116).